. Trajectory groups for condom nonuse over time with percent membership for each trajectory group. The y-axis represents the estimated probability of being classified in condom nonuse categories.
Background. In Botswana, more than 10% of HIV-exposed, uninfected infants (HEU) are hospitalized or die in the first 6 months of life, largely due to infectious causes. Vaccine responses can act as a marker of the immune response to infectious antigens. Previous studies of antibody responses to vaccines in HEU have had conflicting results. We compared antibody titers to tetanus vaccine between HEU and HIV-unexposed infants (HUU), and explored whether tetanus antibody titers predicted risk of hospitalization in the first 2 years of life among HEU.
Methods. 443 HIV-infected and 451 HIV-uninfected mothers and their 453 HEU / 457 HUU live-born infants were followed in a prospective observational study in Botswana ("Tshipidi"). Quantitative tetanus toxoid IgG was measured in plasma samples from 18-month-old infants. Geometric mean antibody titers (GMT) were compared between HEU and HUU infants, and between HEU infants who were or were not hospitalized by age 2.
Results. Plasma was available at 18 months for 39 HEU and 42 HUU infants. Within this subset, there were 15 hospitalizations (12 in HEU) [RR of hospitalization among HEU = 1.34 (P = 0.009)]. 73% of hospitalizations overall, and 83% in HEU, were due to infection (primarily pneumonia/bronchiolitis and gastroenteritis). Among infants who had received 3 or 4 doses of tetanus vaccine by 18 months, there were no significant differences in tetanus GMT between HEU and HUU (Fig A) . Among HEU who had received 3 or 4 doses of tetanus vaccine by 18 months, there were no significant differences in tetanus GMT between infants who were hospitalized and infants who were not (Fig B) .
Conclusion.
In this small sample of infants from Botswana, we did not identify differences in antibody responses to tetanus vaccine between HEU and HUU. Although HEU demonstrated an increased risk of hospitalization, response to tetanus vaccine did not appear to be a significant predictor of morbidity. It is possible that cell-mediated immune defects play a larger role than humoral immune defects in the increased susceptibility to infection among HEU. Background. Dolutegravir (DTG) is a highly efficacious and well tolerated antiretroviral (ART) for the treatment of HIV infection. Although on the preferred treatment list for people living with HIV, it is not a treatment option for pregnant women because data on efficacy, tolerability during pregnancy, and teratogenicity are limited.
Disclosures
Methods. We performed a descriptive cohort analysis of pregnant women from the Drexel Women's Care Center (WCC) receiving DTG for HIV treatment during pregnancy. The Drexel WCC reports maternal and fetal outcomes to the Antiretroviral Pregnancy Registry, a national de-identified database of pregnant women with HIV on ART. Here, we evaluate maternal and fetal outcomes of mother-infant pairs with DTG use during pregnancy between 2015 and 2017.
Results. During the study period, 19 pregnant women used DTG for HIV treatment; 14 had live deliveries and 5 were still pregnant at the time of abstract submission. DTG use was five times higher in 2017 compared with 2015 ( Figure 1 ). All deliveries resulted in live fetuses with negative HIV status, although there was one fetus from a twin pregnancy with a congenital abnormality. The majority of women were diagnosed with HIV before pregnancy (84%), were already on DTG when entering pregnancy (63%) and remained on the same regimen until labor and delivery (Table 1) .
Conclusion. We found that DTG use is increasing among a clinic cohort of pregnant women with HIV with signs of treatment tolerability during pregnancy. The risk of teratogenicity will need to be fully assessed as more clinics report fetal outcomes among infants exposed to DTG.
VF was seen in 29% (94 / 328), while IF was seen in only 3% (10 / 331) of children. 62% of children with VF reported >90% adherence to ART. Of the 94 children with VF, 5 children showed IF. Correlation between VF and IF was absent. Sensitivity (95% CI) of IF to VF was 6% (2.2-14.6), specificity 98% (94.9-99.5), PPV 56% (26.7-81.1) and NPV was 73. 4% (67.8-78.4) . At the time of VF, multiple NNRTI-associated mutations were observed in 80% (52/65) of children -K103N and Y181C were the major NNRTI DRMs onserved. M184V also was observed in 79% of children with VF. No definite predictors of VF could be determined.
Conclusion. Though ART provides significant benefit to children in India, over a quarter of them had VF and developed major drug-resistance mutations after 48 weeks of ART. There is a lack of correlation between IF and VF, leading to delay in identifying treatment failure. Periodic plasma HIV-RNA testing should be performed to detect treatment failures early.
Disclosures. All authors: No reported disclosures. Background. Many women living with HIV (WLWH) fall out of the care continuum after delivery. Existing evidence-based interventions are aimed at increasing retention of WLWH outside the perinatal period but none, in the US, focus on improving retention postpartum. mothers2mothers (m2m) is a peer mentor mother program developed in South Africa and successfully implemented in six African countries, with evidence of increased self-efficacy and retention in HIV care postpartum. Here, we assess the acceptability of an adapted version of m2m in the US.
Assessing the Acceptability of a Community-Based Intervention to
Methods. In depth interviews were conducted with five pregnant and four postpartum WLWH receiving prenatal and HIV care in a Philadelphia clinic, to assess barriers and facilitators to retention in HIV care during pregnancy and postpartum. We also assessed participants' acceptability of m2m with the goal to adapt the program to meet their needs. All interviews were audio-taped, transcribed and analyzed. Codes were developed and applied to all transcripts and matrices were used to facilitate comparisons across different types of participants.
Results. Participants included low-income Black and Hispanic women with a mean age was 35 (range 23-42). Regardless of their stage in the care continuum, women found m2m to be an acceptable intervention to help sustain engagement in care after delivery and discussed ways to tailor the program to fit their needs. Participants reported experiencing trauma related to interpersonal violence and conflicts, stigma from HIV or HIV disclosure, and struggles with substance use. Many experienced depression or had a history of suicidal ideation or attempt. An overarching finding was that women's strongest motivator for staying in care was to protect the health and well-being of their baby. In addition, the majority of women found that family support, especially from their mothers, enhanced their coping skills, and in turn, facilitated their retention in care.
Conclusion. m2m is a promising intervention with the potential to improve the care continuum of WLWH who are pregnant or postpartum. The program will need to be adapted using a trauma informed approach to meet the needs of WLWH. Messaging will need to maximize on maternal support and women's motivation to keep their infant healthy to leverage retention in care postpartum.
Disclosures. Background. Of the 1.8 million children (0-14 y.o.) living with HIV worldwide, over 80% live in sub-Saharan Africa. Children's access to antiretroviral treatment (ART) remains low (est. 63% in east/central Africa), and even with access, long-term adherence is difficult. Uganda has been upheld as a model country for its response to HIV, and therefore offers an ideal place to assess children's adherence.
Objectives: Identify early indicators of treatment failure for children on ART to facilitate health care worker intervention to improve adherence prior to clinical indicators of treatment failure.
Methods. Chart review of 188 case files of children living with HIV in Uganda; systematic univariate and multivariate analysis of demographic, social, and environmental variables which correlate with HIV treatment failure among reintegrated children; semi-structured interviews with staff, caregivers, and children about predictors of treatment failure.
Results. HIV-positive children present late to the program with a mean enrollment age of 9.7 years [n = 137]. Of the HIV-positive children enrolled in the program, one in five (20% [28/137]) had died and 10% [14/137] had rebounded to the center
